2015 - Hersonissos, Crete - Greece

2015 - Hersonissos, Crete - Greece


Tuesday June 2


 14:00-18:30 Registration
 19:30 Welcome reception


Wednesday June 3


08:00-09:00 Registration
09:00-09:15 Welcome and Introduction
09:15-10:45 Targeting Ebola

Chair: Steven Kern

09:15-09:30 Steven Kern Conducting clinical trials in challenging environments
09:30-09:55 France Mentré Estimating an effective dose for a repurposed drug to treat Ebola: the case of favipiravir
09:55-10:20 Matthias Machacek Estimating an effective dose for a new drug to treat Ebola with incomplete information: the case of Zmapp
10:20-10:45 Scott Berry An Adaptive Platform Trial for Ebola: Application to Future Epidemics
10:45-12:15 Coffee break, Poster and Software session I
  Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter
12:15-12:55 Diabetes

Chair: IñakiTrocóniz 

12:15-12:35 Roberto Bizzotto A model of glucose clearance to improve the description of glucose homeostasis
12:35-12:55 Rada Savic A longitudinal HbA1c model elucidates genes linked to disease progression on metformin therapy
12:55-14:25 Lunch
14:25-15:15 On the 20th anniversary of 'Nonlinear models for repeated measurement data'

Chair: France Mentré 

14:25-14:50 David Giltinan Why write a book in 1995 on nonlinear mixed effects modeling?
14:50-15:15 Marie Davidian Subsequent developments in nonlinear mixed effects modeling (link to the video of the presentation)
15:15-16:40 Tea break, Poster and Software session II
  Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter
16:40-17:40 Other diseases

Chair: Ana Ruiz 

16:40-17:00 José David Gómez-Mantilla Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach
17:00-17:20 Gopichand Gottipati Modeling of a composite score in Parkinson’s disease using item response theory
17:20-17:40 Emilie Hénin Determination of effective blood concentrations of cyclosporine in pediatric severe aplastic anemia based on a time-to-response model


Thursday June 4


09:00-10:20 Lewis Sheiner Student Session

Chair: Rada Savic, Steven Kern and Michael Looby

09:00-09:25 Huixin Yu Development of a tumour growth inhibition model to elucidate the effect of ritonavir on intratumoural metabolism and anti-tumour effect of docetaxel in a mouse model for hereditary breast cancer
09:25-09:50 Shan Pan Automated proper lumping for simplification of systems models
09:50-10:15 Adrien Tessier Modelling pharmacogenetic data in population studies during drug development
10.15-10.20 Presentation of Lewis Sheiner student session awards
10:20-11:45 Coffee break, Poster and Software session III
  Posters in Group III (with poster numbers starting with III-) are accompanied by their presenter
11:45-12:50 Applied Bayesian Inference for Pharmacometrics

Chair: Paolo Magni 

11:45-12:05 Michael Betancourt Part I: Building Robust PK/PD Population Models with Bayesian Inference
12:05-12:30 Sebastian Weber Part II: Building Robust PK/PD Population Models with Bayesian Inference
12:30-12:50 Thierry Wendling Application of a Bayesian population approach to physiologically-based modelling and simulation of mavoglurant pharmacokinetics
12:50-14:10 Lunch
14:10-15:10 PKPD and drug resistance in infectious diseases

Chair: Oscar Della Pasqua and Jonathan Mochel 

14:10-14:30 Rong Deng Towards Model-Based Drug Development of New Therapeutics for Hepatitis C Virus
14:30-14:50 Joe Standing Treating resistant Gram-negatives: bedside to bench and back
14:50-15:10 Anders Kristoffersson A PKPD model characterizing resistance for predictions of bacterial kill in vivo
15:10-15:15 Announcement of WCoP 2016

Nick Holford 

15:15-16:30 Tea break, Poster and Software session IV
  Posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter
16:30-17:30 Stuart Beal Methodology Session

Chair: Pascal Girard 

16:30-16:50 Andrew Hooker Preconditioning of nonlinear mixed effect models for stabilization of the covariance matrix computation
16:50-17:10 Eric Strömberg Simulated model based adaptive optimal design of adult to children bridging study using FDA stopping criteria
17:10-17:30 Sebastian Ueckert Alternative to resampling methods in maximum likelihood estimation for NLMEMs by borrowing from Bayesian methodology


Friday June 5


09:15-10:15 Infectious diseases

Chair: Marylore Chenel

09:15-09:35 Joel Tarning Semi-mechanistic time-to-event modelling in malaria
09:35-09:55 Natalie Filmann Modeling the PK/PD of hepatitis B immunoglobulin after hepatitis B induced liver transplantation by an extended target mediated drug disposition model
09:55-10:15 Dimitra Bon Multiscale modelling for hepatitis C treatment
10.15-10.25 Preview of PAGE 2016
10:25-10:55 Coffee break and Software session
10:55-12:15 Modelling in oncology

Chair: Dinesh De Alwis

10:55-11:15 Nadia Terranova Analysis of individual target lesions for tumor size models of drug resistance: a new methodology encompassing signal processing and machine learning
11:15-11:35 Nelleke Snelder PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin – What is the optimal testosterone level?
11:35-11:55 Anna Georgieva Kondic Model-based analysis of the relationship between pembrolizumab exposure and efficacy in patients with melanoma and NSCLC: across indication comparison
11:55-12:15 Pauline Mazzocco Modeling the emergence of resistance in low-grade glioma patients treated with temozolomide, and simulations using a stochastic approach
12.15-12.25 Closing remarks
12:25-12:45 Audience Input for the PAGE 2016 Program